Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03740048 · ClinicalTrials.gov registry record · Phase 3
A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease
A Phase 3 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 51
- Enrollment target
NCT03740048 is a Phase 3 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 51 participants.
The verdict
NCT03740048, a Phase 3 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 51 participants
- Enrollment target
Study Summary
The optimal frequency of hemodialysis treatments in patients with incident end-stage kidney disease in not known. This pilot trial will randomize patients with incident end-stage kidney disease due to chronic kidney disease progression to two different regimens of hemodialysis: i) twice-weekly hemodialysis for six weeks with adjuvant pharmacologic medications followed by thrice-weekly hemodialysis, or ii) thrice-weekly hemodialysis. The study will test feasibility of stepwise hemodialysis, and the effects of the two regimens of hemodialysis on residual kidney function.
Interventions
- OTHER Hemodialysis
- DRUG Patiromer Oral Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2019-06-19 |
| Est. Completion | 2021-11-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03740048
The ClinicalTrials.gov registry entry for NCT03740048 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hemodialysis is the first listed.
NCT03740048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03740048 about?
NCT03740048 is a clinical study titled "A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease". The optimal frequency of hemodialysis treatments in patients with incident end-stage kidney disease in not known. This pilot trial will randomize patients with incident end-stage kidney disease due to chronic kidney disease progression to two different regimens of hemodialysis: i) twice-weekly hemod...
What is the current status of trial NCT03740048?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 51 participants. The study started on 2019-06-19. Estimated completion is 2021-11-04.
What interventions are being tested in trial NCT03740048?
The interventions under investigation include: Hemodialysis (OTHER), Patiromer Oral Product (DRUG).
Who is sponsoring clinical trial NCT03740048?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.